Scribe Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
SCTX•Second-quarter financial results
Sept. 2 (Reuters) - Scribe Therapeutics Inc SCTX.O:
- Scribe Therapeutics reports second quarter 2026 financial results and recent corporate highlights
- Scribe Therapeutics - Q2 2026 collaboration revenue $1.90 million versus $4.90 million in Q2 2025
- Scribe Therapeutics - Q2 2026 net loss $6.50 million or $2.62 per share versus $9.90 million or $4.08 per share in Q2 2025
